酒精使用障碍住院患者的肝病学和成瘾治疗一体化可改善结局：一项前瞻性研究。
Integrated hepatology and addiction care for inpatients with alcohol use disorder improves outcomes: a prospective study.
机构信息
MGH Alcohol Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Hepatol Commun. 2023 Apr 26;7(5). doi: 10.1097/HC9.0000000000000119. eCollection 2023 May 1.
BACKGROUND
Growing literature highlights the need to integrate hepatology and addiction care to improve outcomes for patients with alcohol use disorder and alcohol-associated liver disease. However, prospective data for this approach are lacking.
METHODS
We prospectively examined the efficacy of an integrated hepatology and addiction medicine approach on alcohol use and hepatology outcomes in inpatients with alcohol use disorder.
FINDINGS
An integrated approach improved the uptake of medical alcohol therapy, hepatic fibrosis screening, and viral hepatitis vaccination compared with a historical control of patients who received addiction medicine care alone. There were no differences in the rates of early alcohol remission. The integration of hepatology and addiction care may improve outcomes in patients with alcohol use disorder.
背景
越来越多的文献强调需要将肝脏病学和成瘾治疗相结合，以改善酒精使用障碍和酒精相关肝病患者的治疗效果。然而，目前缺乏这种方法的前瞻性数据。
方法
我们前瞻性地研究了在酒精使用障碍住院患者中采用肝脏病学和成瘾医学相结合的方法对酒精使用和肝脏病学结果的疗效。
结果
与仅接受成瘾医学治疗的历史对照组相比，综合治疗方法提高了医疗性酒精治疗、肝纤维化筛查和病毒性肝炎疫苗接种的采用率。早期酒精缓解率没有差异。将肝脏病学和成瘾治疗相结合可能会改善酒精使用障碍患者的治疗效果。
Zotero 插件